Suppr超能文献

2017年至2021年新的药品不良反应信号——真实警报还是虚惊一场?

New Adverse Drug Reaction Signals from 2017 to 2021-Genuine Alerts or False Alarms?

作者信息

Loke Yoon Kong, Mattishent Katharina, Navaneetharaja Navena

机构信息

Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK.

出版信息

Pharmacy (Basel). 2024 Feb 10;12(1):33. doi: 10.3390/pharmacy12010033.

Abstract

Spontaneous adverse events reporting systems are used internationally to flag new or unexpected adverse drug reactions (ADRs). Disproportionality analysis is a recognised technique, but false alarms may arise. We aimed to determine whether these new ADR signals had subsequently been followed-up with detailed hypothesis-testing studies. We searched PubMed to identify published studies (years 2017-2021) where the authors reported findings of new ADR signals from disproportionality analyses. We used PubMed and forward citation tracking (Google Scholar) to identify any subsequent confirmatory studies of these ADR signals. We screened 414 titles and abstracts and checked the full-text articles of 57 studies. We found signals for 56 suspected new ADRs from 24 drugs. Google Scholar showed that the ADR studies had been cited a median of seven times (range 0-61). However, none of the suspected new ADRs had undergone detailed evaluation in the citing literature. Similarly, our PubMed search did not find any confirmation studies for the 56 suspected new ADRs. Although many suspected new ADR signals have been identified through disproportionality analysis, most signals have not been further verified as being either genuine ADRs or false alarms. Researchers must focus on follow-up studies for these new signals.

摘要

自发不良事件报告系统在国际上被用于标记新的或意外的药物不良反应(ADR)。不成比例分析是一种公认的技术,但可能会出现误报。我们旨在确定这些新的ADR信号随后是否进行了详细的假设检验研究。我们检索了PubMed以识别已发表的研究(2017 - 2021年),其中作者报告了来自不成比例分析的新ADR信号的研究结果。我们使用PubMed和正向引文追踪(谷歌学术)来识别这些ADR信号随后的任何验证性研究。我们筛选了414个标题和摘要,并检查了57项研究的全文文章。我们从24种药物中发现了56种疑似新ADR的信号。谷歌学术显示,ADR研究的被引用中位数为7次(范围0 - 61)。然而,在引用文献中,没有一种疑似新ADR经过详细评估。同样,我们在PubMed搜索中也未找到针对这56种疑似新ADR的任何确认性研究。尽管通过不成比例分析已经识别出许多疑似新ADR信号,但大多数信号尚未进一步验证是真正的ADR还是误报。研究人员必须专注于对这些新信号的后续研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0421/10892108/6a1a018eb2f4/pharmacy-12-00033-g001.jpg

相似文献

1
New Adverse Drug Reaction Signals from 2017 to 2021-Genuine Alerts or False Alarms?
Pharmacy (Basel). 2024 Feb 10;12(1):33. doi: 10.3390/pharmacy12010033.
5
Safety analysis of therapeutic drugs for breast cancer patients and construction of a predictive model for serious adverse drug reactions.
Eur J Clin Pharmacol. 2024 Feb;80(2):249-259. doi: 10.1007/s00228-023-03604-2. Epub 2023 Dec 15.
6
Signals of Adverse Drug Reactions Communicated by Pharmacovigilance Stakeholders: A Scoping Review of the Global Literature.
Drug Saf. 2023 Feb;46(2):109-120. doi: 10.1007/s40264-022-01258-0. Epub 2022 Dec 5.

引用本文的文献

2
EudraVigilance insights: Suspected adverse drug reactions in infants through breastfeeding.
Br J Clin Pharmacol. 2025 Aug;91(8):2431-2436. doi: 10.1002/bcp.70063. Epub 2025 Apr 6.
3
The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline.
Front Pharmacol. 2024 Nov 27;15:1488725. doi: 10.3389/fphar.2024.1488725. eCollection 2024.
4
Not Just Another Reporting Guideline? Here's Why READUS-PV is a Major Step Forward.
Drug Saf. 2024 Jun;47(6):571-573. doi: 10.1007/s40264-024-01441-5. Epub 2024 May 8.

本文引用的文献

1
Pharmacovigilance studies without a priori hypothesis: systematic review highlights inappropriate multiple testing correction procedures.
J Clin Epidemiol. 2023 Oct;162:127-134. doi: 10.1016/j.jclinepi.2023.08.010. Epub 2023 Aug 31.
2
Transparency and robustness of safety signals.
BMJ. 2022 Nov 3;379:o2588. doi: 10.1136/bmj.o2588.
3
Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: A call to action.
Br J Clin Pharmacol. 2022 Jul;88(7):3535-3536. doi: 10.1111/bcp.15269. Epub 2022 Feb 17.
5
Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS.
Front Pharmacol. 2021 Dec 20;12:766125. doi: 10.3389/fphar.2021.766125. eCollection 2021.
10
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system.
Expert Opin Drug Saf. 2021 Nov;20(11):1421-1431. doi: 10.1080/14740338.2021.1956461. Epub 2021 Jul 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验